within Pharmacolibrary.Drugs.ATC.N;

model N03AX19
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.92,
    Cl             = 9.5e-07,
    adminDuration  = 600,
    adminMass      = 800 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.010166666666666666,
    Tlag           = 15.0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N03AX19</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Carisbamate is a novel neuromodulator and anticonvulsant that acts as an antiepileptic agent. It was investigated for the treatment of partial seizures and other CNS conditions but was not approved by the FDA or any other major regulatory authority for market use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers following single oral dosing.</p><h4>References</h4><ol><li><p>Novak, GP, et al., &amp; Klein, B (2007). Carisbamate (RWJ-333369). <i>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</i> 4(1) 106–109. DOI:<a href=\"https://doi.org/10.1016/j.nurt.2006.11.016\">10.1016/j.nurt.2006.11.016</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17199023/\">https://pubmed.ncbi.nlm.nih.gov/17199023</a></p></li><li><p>Zannikos, P, et al., &amp; Bialer, M (2009). Pharmacokinetics of carisbamate (RWJ-333369) in healthy Japanese and Western subjects. <i>Epilepsia</i> 50(8) 1850–1859. DOI:<a href=\"https://doi.org/10.1111/j.1528-1167.2009.02081.x\">10.1111/j.1528-1167.2009.02081.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19453703/\">https://pubmed.ncbi.nlm.nih.gov/19453703</a></p></li><li><p>Levy, R, et al., &amp; Novak, G (2008). Pharmacokinetics, safety, and tolerability of the new antiepileptic carisbamate in the elderly. <i>Epilepsy research</i> 79(1) 22–30. DOI:<a href=\"https://doi.org/10.1016/j.eplepsyres.2007.12.013\">10.1016/j.eplepsyres.2007.12.013</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18280116/\">https://pubmed.ncbi.nlm.nih.gov/18280116</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N03AX19;
